ARID1A and lung carcinoma: Moreover, the results showed that ARID1A depletion could promote lung cancer cell proliferation and decrease sensitivity to the conventional chemotherapies, possibly by Akt-mediated cyclin D1 and Bcl-2 regulation (Zhang et al., 2014).